Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30905277 | 0.84 | POLB (0.82) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL5766288 | 0.80 | SMN1; SMN2 (0.53) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL4477912 | 0.77 | MEN1 (0.63) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL9186295 | 0.77 | MEN1 (0.77) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL29880432 | 0.75 | POLB (1.00) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL10688767 | 0.75 | POLB (1.00) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL15712170 | 0.74 | HDAC1 (0.69) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL4321402 | 0.74 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL9190101 | 0.74 | MEN1 (0.76) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL13960741 | 0.73 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476675-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1603880-B1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1603880-B1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1603880-A1 | QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-11-24 | — | — | US | disclosed |
| US-6943169-B2 | Quinolinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004080969-A1 | QUINOLINONE / BENZOXAZINONE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | ROCHE PALO ALTO LLC | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186092-A1 | Quinolinone derivaties and uses thereof | NQO2, UGT1A8, UGT1A1 | MEN1 433/4885KMT2A 935/4885SMN1; SMN2 3996/4885 |
| US-20050261308-A1 | Quinolinone derivatives and uses thereof | RECQL, NQO2, QRFPR | MEN1 496/4885KMT2A 1510/4885SMN1; SMN2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.